Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapiglutide - Zealand Pharma

Next Previous
Drug Profile

Dapiglutide - Zealand Pharma

Alternative Names: Dual GLP-1R/GLP-2R agonist - Zealand Pharma; Dual-acting peptide therapeutic - Zealand Pharma; Dual-GLP-1/GLP-2 acting peptide - Zealand Pharma; GLP-1/GLP-2 receptor agonist - Zealand Pharma; ZP-7570

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Class Obesity therapies; Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity
  • No development reported Gastrointestinal disorders; Short bowel syndrome

Most Recent Events

  • 20 Jun 2025 Adverse events, pharmacokinetics and pharmacodynamics data from a phase Ib trial in Obesity presented at the 85th Annual Scientific Sessions of the American Diabetes Association (ADA-2025)
  • 18 Jun 2025 Efficacy and adverse events data from a phase Ib trial in Obesity released by Zealand Pharma
  • 08 May 2025 Zealand Pharma plans a phase IIb trial for Obesity in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top